Table 5. Versican isoforms predict the clinical course on top of traditional risk factors – analysis of the whole cohort.

Whole cohort (n = 74)
	Creatinine at follow-up
Univariate model	parameter estimate	p-value	adj R2
Creatinine at biopsy	0.6372	0.0019	0.1155
Proteinuria at biopsy	0.0249	0.7930	<0
TAIF	0.4871	0.1520	0.0150
II	0.3773	0.2440	0.0053
GS	0.8050	0.0045	0.0983
Versican V0	339.3458	0.0033	0.1026
Versican V1	49.9941	0.0006	0.1421
	Creatinine at follow-up
Model 1	parameter estimate	p-value	adj R2
Creatinine at biopsy	0.5004	0.0149
GS	0.5768	0.0429
total		0.0009	0.1619
	Creatinine at follow-up
Model 2	parameter estimate	p-value	adj R2
GS	0.5284	0.0579
Creatinine at biopsy	0.4294	0.0342
Versican V0	232.2049	0.0411
total		0.0004	0.2012
	Creatinine at follow-up
Model 3	parameter estimate	p-value	adj R2
GS	0.6947	0.0119
Creatinine at biopsy	0.3414	0.0894
Versican V1	41.2212	0.0052
total		0.0001	0.2438
	Creatinine at follow-up
Model 4	parameter estimate	p-value	adj R2
Creatinine at biopsy	0.3364	0.0978
GS	0.7207	0.0141
Versican V0	−51.2110	0.7789
Versican V1	46.5995	0.0552
total		0.0002	0.2333

For abbreviations see table 3 or 4.